Oneness Biotech (4743)

Executive Summary

Oneness Biotech is a Taiwan-based public biopharmaceutical company focused on developing novel therapeutics for unmet medical needs in dermatology, immunology, infectious diseases, metabolism, and wound care. Founded in 2008, the company leverages its in-house discovery platform to advance small-molecule and formulation candidates. Its lead asset, FESPIXON® cream (ON101), is a topical agent for diabetic foot ulcers currently in Phase 3 clinical trials, addressing a large and growing market with high unmet need. The pipeline also includes candidates for atopic dermatitis, severe asthma, COVID-19 infection, and weight loss, targeting indications with significant commercial potential. Oneness Biotech is at a critical juncture as it awaits Phase 3 results for ON101, which if positive could lead to regulatory filings in key markets and potential commercialization partnerships. The company's diverse pipeline and public listing (Ticker: 4743) provide visibility, but execution risk remains given the early stage of most programs. Near-term catalysts include ON101 data readout and progress in other indications. With a strong focus on dermatology and wound care, Oneness Biotech is positioned to address significant therapeutic gaps, though investor attention will hinge on Phase 3 outcomes.

Upcoming Catalysts (preview)

• Q3 2026ON101 Phase 3 top-line data for diabetic foot ulcers55% success
• TBDInitiation of Phase 2/3 trial for atopic dermatitis candidate40% success
• TBDPartnership or licensing deal for ON101 in ex-Asia markets50% success